Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
Amy Leblanc | X | |
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
Ralph Parchment | X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
- Kuffel, Gina (NIH/NCI) [C] to send out message to SC members about upcoming talk from Lee Helman and Julia Labadie
- Toby to reach out to Adam Resnick to gauge interest in joining the Subcommittee
- Kuffel, Gina (NIH/NCI) [C] to work with Ralph to get the letters prepared for the new SC members
- Kuffel, Gina (NIH/NCI) [C] to build list of studies that used FidoCure data
- Revisit new steering committee members in September (loop Connie into this discussion)
- Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background
Agenda
Item | Who | Talking Points |
---|---|---|
ICDC Common Data Element (CDE) Mapping Exercise | ICDC Model Properties 2024-05-31 - working copy.xlsx | |
Recent & Upcoming Presentations |
| |
Steering Committee Updates | Ralph |
|
Longitudinal Data Acquisition and Use Working Group (LDAUWG) Updates | All |
|
Data Governance Advisory Board (DGAB) Updates | ICDC Incoming Data Submission Requests
ICDC Studies Recently Approved
ICDC Studies in Active Submission OSA04
COTC021
COTC022
UBC03
OSA02
PRECINCT01
PRECINCT02
| |
ICDC Biospecimen Data |
| |
Next Executive Team Meeting |
|
Minutes (Not Verbatim)
RP - Coordinated Leidos subcontracts to provide electronic data capture that they typically would have collected. This would be deployed to the COP sites that want to participate. During follow-up care data points will be collected. COTC sites have the medical expertise to process samples. Might roll this out as a study, may focus on paper data capture. Sequencing may be done by the Broad and Matthew Breen.
TH - These conversations have not materialized for over 2 years. LDAUWG will advise on how to collect, what to collect, and analysis guidance.
RP - The GRLS study is interested in involving us. We willl commit the funds through the PRs. 1 for GRLS and MAF, 1 for Tufts and metadata collection using the Dog Aging templates from Dan Promislow, and 1 for COTC clinical trial sites that want to participate. We can ask through the RFP if any groups want to volunteer for the sequencing effort. As part of the RFP we can include around 6 cancer-free senior individuals.
Notes on FidoCure
- Not clear if we really can have a successful collaboration, however we have let them know if they can find a way to work with us that the ICDC would be interested.
- Their public data is a candidate for the ICDC
- They are interested in correlating data with biomarkers and that is an area of interest for the ICDC
- Work instead with peer reviewed and published scientists that use FidoCure data
- Their data may not be useful to predict outcomes
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items